Avelumab Plus Intermittent Axitinib in Previously Untreated Patients with Metastatic Renal Cell Carcinoma. The Tide-A Phase 2 Study

• DOI: 10.1016/j.eururo.2024.02.014
• Publication Date: 2024-03-22T20:24:05Z
• Authors: Roberto Iacovelli; Chiara Ciccarese; Sebastiano Buti; Paolo Andrea Zucali; Emanuela Fantinel; Davide Bimbatti; Elena Verzoni; Caterina Accettura; Lucia Bonomi; Consuelo Buttigliero; Giuseppe Fornarini; Stefania Pipitone; Francesco Atzori; Cristina Masini; Francesco Massari; Francesca Primi; Alessandro Strusi; Giulia Claire Giu...; Matteo Perrino; Marco Maruzzo; Michele Milella; Diana Giannarelli; Matteo Brunelli; Giuseppe Procopio; Giampaolo Tortora
• Keywords: Axitinib; Clinical endpoint; Avelumab; Tolerability

Combinations of VEGFR-TKIs plus ICI against PD1/PD-L1 are the standard first-line therapy for patients with mRCC, irrespective prognostic class. This study aims to investigate feasibility and safety withdrawing VEGFR-TKI but continuing anti- in who achieve response their combination.